PHASE-II TRIAL AND COST-ANALYSIS OF FAZARABINE IN ADVANCED NON-SMALL-CELL CARCINOMA OF THE LUNG - A SOUTHWEST-ONCOLOGY-GROUP STUDY

被引:33
|
作者
WILLIAMSON, SK
CROWLEY, JJ
LIVINGSTON, RB
PANELLA, TJ
GOODWIN, JW
机构
[1] SW ONCOL GRP,CTR STAT,SEATTLE,WA
[2] UNIV WASHINGTON,SEATTLE,WA
[3] THOMPSON CANC SURVIVAL CTR,KNOXVILLE,TN
[4] OZARKS REG CCOP,SPRINGFIELD,MO
关键词
FAZARABINE; NUCLEOSIDES; COST ANALYSIS; LUNG NEOPLASMS;
D O I
10.1007/BF02614223
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods: Twenty-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion at 2.0 mg/M(2)/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results: There were no responses (0%, 95% confidence interval = 0-15%) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions: Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.
引用
收藏
页码:67 / 71
页数:5
相关论文
共 50 条
  • [41] PHASE-II TRIAL OF DIMETHYLTRIAZENOIMIDAZOLE CARBOXAMIDE IN PATIENTS WITH METASTATIC CARCINOID - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    BUKOWSKI, RM
    TANGEN, CM
    PETERSON, RF
    TAYLOR, SA
    RINEHART, JJ
    EYRE, HJ
    RIVKIN, SE
    FLEMING, TR
    MACDONALD, JS
    CANCER, 1994, 73 (05) : 1505 - 1508
  • [42] PHASE-II TRIAL OF DIANHYDROGALACTITOL IN METASTATIC MALIGNANT-MELANOMA - SOUTHWEST-ONCOLOGY-GROUP STUDY
    THIGPEN, JT
    ALSARRAF, M
    HEWLETT, JS
    CANCER TREATMENT REPORTS, 1979, 63 (04): : 525 - 528
  • [43] PHASE-II TRIAL OF MERBARONE IN SOFT-TISSUE SARCOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    KRAUT, EH
    BENDETTI, J
    BALCERZAK, SP
    DOROSHOW, JH
    INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) : 347 - 349
  • [44] PHASE-II TRIAL OF PIROXANTRONE IN METASTATIC BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    RAVDIN, PM
    GREEN, S
    DOROSHOW, JH
    MARTINO, S
    INVESTIGATIONAL NEW DRUGS, 1994, 12 (04) : 333 - 336
  • [45] PHASE-II TRIAL OF M-AMSA IN GALLBLADDER AND CHOLANGIOCARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    BUKOWSKI, RM
    LEICHMAN, LP
    RIVKIN, SE
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (06): : 721 - 723
  • [46] PHASE-II STUDY OF AMSACRINE (META-AMSA) IN ADVANCED LYMPHOMAS - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    WEICK, JK
    JONES, SE
    RYAN, DH
    CANCER TREATMENT REPORTS, 1983, 67 (05): : 489 - 492
  • [47] Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study
    D. R. Gandara
    Martin J. Edelman
    John J. Crowley
    Derick H. M. Lau
    Robert B. Livingston
    Cancer Chemotherapy and Pharmacology, 1997, 41 : 75 - 78
  • [48] Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study
    Gandara, DR
    Edelman, MJ
    Crowley, JJ
    Lau, DHM
    Livingston, RB
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 41 (01) : 75 - 78
  • [49] A PHASE-II TRIAL OF CONTINUOUS-INFUSION RECOMBINANT INTERLEUKIN-2 IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    WHITEHEAD, RP
    WOLF, MK
    SOLANKI, DL
    HEMSTREET, GP
    BENEDETTO, P
    RICHMAN, SP
    FLANIGAN, RC
    CRAWFORD, ED
    JOURNAL OF IMMUNOTHERAPY, 1995, 18 (02) : 104 - 114
  • [50] PHASE-II TRIAL OF PIROXANTRONE IN PATIENTS WITH RECURRENT AND METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A SOUTHWEST-ONCOLOGY-GROUP TRIAL
    TAYLOR, SA
    BENEDETTI, J
    SCHULLER, D
    RICHMAN, SP
    BROUN, GO
    HANTEL, A
    INVESTIGATIONAL NEW DRUGS, 1993, 11 (2-3) : 227 - 229